Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
25021-0222-01 25021-0222 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2013 March 31, 2017 No Longer Used
25021-0222-04 25021-0222 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2013 March 31, 2017 No Longer Used
25021-0222-07 25021-0222 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2013 March 31, 2017 No Longer Used
43598-0258-11 43598-0258 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 10, 2014 In Use
43598-0611-11 43598-0611 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 22, 2017 In Use
45963-0765-52 45963-0765 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 1, 2014 In Use
25021-0245-01 25021-0245 Docetaxel Anhydrous Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 15, 2017 In Use
25021-0245-04 25021-0245 Docetaxel Anhydrous Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 15, 2017 In Use
42023-0111-01 42023-0111 Estradiol Valerate Delestrogen 20.0 mg/mL Hormonal Therapy Estrogen Intramuscular Nov. 1, 2007 In Use
00173-0821-01 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous July 22, 2011 Aug. 31, 2017 No Longer Used
00173-0821-02 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous July 22, 2011 Aug. 31, 2017 No Longer Used
00173-0821-33 00173-0821 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous July 22, 2011 Aug. 31, 2017 No Longer Used
00409-0369-01 00409-0369 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 28, 2017 March 28, 2017 No Longer Used
72485-0214-01 72485-0214 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 15, 2020 In Use
00009-0274-01 00009-0274 Methylprednisolone Acetate Depo-Medrol 20.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intralesional, Intramuscular, Intrasynovial, Soft Tissue May 28, 1959 In Use
00078-0690-61 00078-0690 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb. 1, 2016 In Use
50090-1523-01 50090-1523 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Human Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
50090-1523-09 50090-1523 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Human Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
00006-4045-00 00006-4045 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
00006-4045-01 00006-4045 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
00006-4045-41 00006-4045 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
00006-4109-01 00006-4109 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
00006-4109-02 00006-4109 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use
00006-4109-06 00006-4109 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 May 6, 2011 In Use
00006-4109-09 00006-4109 Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant GARDASIL 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular June 8, 2006 In Use

Found 10,000 results in 10 millisecondsExport these results